Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have reported new dopamine D1 and/or D5 receptor partial agonists. As such, they are reported to be useful for the treatment schizophrenia, attention deficit hyperactivity disorder (ADHD), Tourette disease, sleep disorder, pain, autism spectrum disorder, Parkinson’s and Alzheimer’s disease, among others.